Foghorn Therapeutics Announces First Patient Dosed in Phase 1 Combination Study of FHD-286 for Relapsed and/or Refractory AML

Foghorn® Therapeutics, Inc. announced the first patient has been dosed in the Phase I study of FHD-286 in combination with decitabine or cytarabine in relapsed and/or refractory AML.
[Foghorn® Therapeutics, Inc.]
Press Release